留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

孤儿核受体NR4A1与动脉粥样硬化的研究进展

干润 霍炎 黄金路 杨全军 郭澄

干润, 霍炎, 黄金路, 杨全军, 郭澄. 孤儿核受体NR4A1与动脉粥样硬化的研究进展[J]. 药学实践与服务, 2016, 34(4): 292-296. doi: 10.3969/j.issn.1006-0111.2016.04.002
引用本文: 干润, 霍炎, 黄金路, 杨全军, 郭澄. 孤儿核受体NR4A1与动脉粥样硬化的研究进展[J]. 药学实践与服务, 2016, 34(4): 292-296. doi: 10.3969/j.issn.1006-0111.2016.04.002
GAN Run, HUO Yan, HUANG Jinlu, YANG Quanjun, GUO Cheng. Research progress on orphan nuclear receptor NR4A1 in atherosclerosis[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 292-296. doi: 10.3969/j.issn.1006-0111.2016.04.002
Citation: GAN Run, HUO Yan, HUANG Jinlu, YANG Quanjun, GUO Cheng. Research progress on orphan nuclear receptor NR4A1 in atherosclerosis[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 292-296. doi: 10.3969/j.issn.1006-0111.2016.04.002

孤儿核受体NR4A1与动脉粥样硬化的研究进展

doi: 10.3969/j.issn.1006-0111.2016.04.002
基金项目: 国家自然科学基金(81503155);上海市科委基金(14ZR1432200);上海交通大学医工交叉项目(YG2014MS21)

Research progress on orphan nuclear receptor NR4A1 in atherosclerosis

  • 摘要: 孤儿核受体NR4A1是尚未发现特异性配体的转录因子之一,属于NR4A亚家族。早期研究发现,NR4A1可通过改变基因表达、翻译后修饰以及辅调蛋白间相互作用,调控细胞的增殖、凋亡、分化和应激反应。近年来研究发现其在动脉粥样硬化损伤部位表达异常,被认为是血管细胞功能紊乱过程中的关键调节基因。通过调控NR4A1基因的表达,可对平滑肌细胞的增殖和内皮细胞的激活产生重要影响,同时能够减少炎症反应、减少泡沫细胞的形成以及脂质沉积,抑制血管重塑,预防和阻止动脉粥样硬化的发生与发展。这些研究显示NR4A1可能成为研发预防和治疗动脉粥样硬化药物的新靶点。
  • [1] Hollman DA, Milona A, van Erpecum KJ, et al. Anti-inflammatory and metabolic actions of FXR:insights into molecular mechanisms[J]. Biochim Biophys Acta, 2012, 1821(11):1443-1452.
    [2] Xiao X, Wang P, Chou KC. Recent progresses in identifying nuclear receptors and their families[J]. Curr Top Med Chem, 2013, 13(10):1192-1200.
    [3] 聂鹏. NR4A孤儿核受体亚家族与动脉粥样硬化[J]. 心血管病学进展,2011,32(5):640-644.
    [4] Milbrandt J. Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene[J]. Neuron, 1988, 1(3):183-188.
    [5] Baker KD, Shewchuk LM, Kozlova T, et al. The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway[J]. Cell, 2003, 113(6):731-742.
    [6] Wang WJ, Wang Y, Chen HZ, et al. Orphan nuclear receptor TR3 acts in autophagic cell death via mitochondrial signaling pathway[J]. Nat Chem Biol, 2014, 10(2):133-140.
    [7] Kurakula K, Koenis DS, van Tiel CM, et al. NR4A nuclear receptors are orphans but not lonesome[J]. Biochim Biophys Acta, 2014, 1843(11):2543-2555.
    [8] Libby P. History of discovery:inflammation in atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2012, 32(9):2045-2051.
    [9] de Vries CJM, van Achterberg TAE, Horrevoets AJG, et al. Differential display identification of 40 genes with altered expression in activated human smooth muscle cells:local expression in atherosclerotic lesions of smags, smooth muscle activation-specific genes[J]. J Biol Chem, 2000, 275(31):23939-23947.
    [10] Arkenbout EK, de Waard V, van Bragt M, et al. Protective function of transcription factor TR3 orphan receptor in atherogenesis:decreased lesion formation in carotid artery ligation model in TR3 transgenic mice[J]. Circulation, 2002, 106(12):1530-1535.
    [11] Pires NM, Pols TW, de Vries MR, et al. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation[J]. Circulation, 2007, 115(4):493-500.
    [12] Bonta PI, Matlung HL, Vos M, et al. Nuclear receptor Nur77 inhibits vascular outward remodelling and reduces macrophage accumulation and matrix metalloproteinase levels[J]. Cardiovasc Res, 2010, 87(3):561-568.
    [13] Kim HJ, Kim JY, Lee SJ, et al. α-Lipoic acid prevents neointimal hyperplasia via induction of p38 mitogen-activated protein kinase/Nur77-mediated apoptosis of vascular smooth muscle cells and accelerates postinjury reendothelialization[J]. Arterioscler Thromb Vasc Biol, 2010, 30(11):2164-2172.
    [14] Cui M, Cai Z, Chu S, et al. Orphan nuclear receptor Nur77 inhibits angiotensin Ⅱ-induced vascular remodeling via downregulation of β-catenin[J]. Hypertension, 2016, 67(1):153-162.
    [15] Yu Y, Cai Z, Cui M, et al. The orphan nuclear receptor Nur77 inhibits low shear stress-induced carotid artery remodeling in mice[J]. Int J Mol Med, 2015, 36(6):1547-1555.
    [16] Bonta PI, van Tiel CM, Vos M, et al. Nuclear orphan receptors Nur77, Nurr1 and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses[J]. Arterioscler Thromb Vasc Biol, 2006, 26(10):2288-2294.
    [17] Pei L, Castrillo A, Chen M, et al. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli[J]. J Biol Chem, 2005, 280(32):29256-29262.
    [18] Pei L, Castrillo A, Tontonoz P. Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77[J]. Mol Endocrinol, 2006, 20(4):786-794.
    [19] Shao Q, Shen LH, Hu LH, et al. Nuclear receptor Nur77 suppresses inflammatory response dependent on COX-2 in macrophages induced by oxLDL[J]. J Mol Cell Cardiol, 2010, 49(2):304-311.
    [20] Hanna RN, Shaked I, Hubbeling HG, et al. NR4A1(Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis[J]. Circ Res, 2012, 110(3):416-427.
    [21] Hu YW, Zhang P, Yang JY, et al. Nur77 decreases atherosclerosis progression in apoE(-/-) mice fed a high-fat/high-cholesterol diet[J]. PLoS ONE, 2014, 9(1):e87313.
    [22] Gruber F, Hufnagl P, Hofer-Warbinek R, et al. Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1(PAI-1) promoter regulates TNF alpha-induced PAI-1 expression[J]. Blood, 2003, 101(8):3042-3048.
    [23] You B, Jiang YY, Chen S, et al. The orphan nuclear receptor Nur77 suppresses endothelial cell activation through induction of Ikappa Balpha expression[J]. Circ Res, 2009, 104(6):742-749.
    [24] Zeng H, Qin L, Zhao D, et al. Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity[J]. J Exp Med, 2006, 203(3):719-729.
    [25] Yang P, Wei X, Zhang J, et al. Antithrombotic effects of Nur77 and Nor1 are mediated through upregulating thrombomodulin expression in endothelial cells[J]. Arterioscler Thromb Vasc Biol, 2015, 36(2):361-369.
    [26] Qin Q, Chen M, Yi B, et al. Orphan nuclear receptor Nur77 is a novel negative regulator of endothelin-1 expression in vascular endothelial cells[J]. J Mol Cell Cardiol, 2014, 77:20-28.
    [27] Zhan Y, Du X, Chen H, et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77[J]. Nat Chem Biol, 2008, 4(9):548-556.
    [28] Huo Y, Yi B, Chen M, et al. Induction of Nur77 by hyperoside inhibits vascular smooth muscle cell proliferation and neointimal formation[J]. Biochem Pharmacol, 2014, 92(4):590-598.
    [29] Pekarsky Y, Hallas C, Palamarchuk A, et al. Akt phosphorylates and regulates the orphan nuclear receptor Nur77[J]. Proc Natl Acad Sci (USA), 2001, 98(7):3690-3694.
    [30] Lee SO, Li X, Hedrick E, et al. Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells[J]. Mol Endocrinol, 2014, 28(10):1729-1739.
  • [1] 张修平, 田家盛, 王道鑫, 李佳鑫, 王品, 缪朝玉.  MT-1207对血糖、血脂和动脉粥样硬化的作用 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202306011
    [2] 王智聪, 谢彬, 袁星, 徐希科, 柳润辉.  基于网络药理学探讨麝香保心丸治疗动脉粥样硬化作用机制 . 药学实践与服务, 2023, 41(5): 296-301. doi: 10.12206/j.issn.2097-2024.202112001
    [3] 王道鑫, 张添光, 缪朝玉.  血管内皮细胞线粒体氧化应激与动脉粥样硬化 . 药学实践与服务, 2023, 41(6): 329-334, 392. doi: 10.12206/j.issn.2097-2024.202205116
    [4] 谢彬, 袁星, 徐希科, 柳润辉.  中药复方抗动脉粥样硬化作用机制的研究进展 . 药学实践与服务, 2021, 39(4): 295-298, 304. doi: 10.12206/j.issn.1006-0111.202103001
    [5] 王品, 齐齐, 郑斯莉, 徐浩展, 缪朝玉.  动脉粥样硬化高脂饲料对小鼠糖脂水平的作用研究 . 药学实践与服务, 2021, 39(2): 121-125. doi: 10.12206/j.issn.1006-0111.202012002
    [6] 赖彦岚, 黄爱文, 张丽丽, 廖小兰, 赵丽君, 宋洪涛.  SGLT-2抑制剂和GLP-1受体激动剂的心血管安全性研究进展 . 药学实践与服务, 2020, 38(6): 496-500, 567. doi: 10.12206/j.issn.1006-0111.202006061
    [7] 林张军, 李倩, 章越凡, 芮耀诚.  巨噬源性泡沫细胞中p62蛋白上调作用和机制的研究 . 药学实践与服务, 2019, 37(5): 400-405,426. doi: 10.3969/j.issn.1006-0111.2019.05.004
    [8] 钱俞君, 秦春霞, 孙莉莉, 丁华敏, 李铁军.  建立以HIF-1α为靶标的高通量筛选防治动脉粥样硬化先导化合物的细胞模型 . 药学实践与服务, 2019, 37(1): 27-31. doi: 10.3969/j.issn.1006-0111.2019.01.007
    [9] 黄瑾, 刘景雪, 曾颖, 袁芳.  胰腺癌细胞中TRPV1受体参与EGFR介导的细胞功能研究 . 药学实践与服务, 2018, 36(2): 126-130. doi: 10.3969/j.issn.1006-0111.2018.02.007
    [10] 杨喜晶, 周福平, 张迁, 钱其军.  乙肝肝硬化并发皮下脂膜炎样T细胞淋巴瘤伴噬血细胞综合征的治疗分析 . 药学实践与服务, 2015, 33(4): 363-365. doi: 10.3969/j.issn.1006-0111.2015.04.019
    [11] 李倩, 芮耀诚.  Lox-1—心血管疾病防治的新靶标 . 药学实践与服务, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001
    [12] 毛峻琴, 侯中海, 陈大贵, 张文.  贻贝多糖MA对实验性动脉粥样硬化兔的作用 . 药学实践与服务, 2014, 32(1): 27-30. doi: 10.3969/j.issn.1006-0111.2014.01.007
    [13] 刘佃花, 张恩晖, 刘冲, 范博士, 蔡国君.  烟碱致动脉粥样硬化的N胆碱受体信号通路 . 药学实践与服务, 2014, 32(2): 81-84. doi: 10.3969/j.issn.1006-0111.2014.02.001
    [14] 李帆, 芮耀诚.  IRAK-4在白介素-1受体/Toll样受体(IL-1R/TLRs)介导的炎症信号通路中的关键作用 . 药学实践与服务, 2011, 29(1): 1-3,14.
    [15] 任天舒, 李林鹏, 姜远英.  高胆固醇血症大鼠自由基代谢紊乱及阿托伐他汀的干预作用 . 药学实践与服务, 2007, (3): 143-144,149.
    [16] 陈巧玲, 蔡宝祥.  他汀类药物防治动脉粥样硬化作用研究进展 . 药学实践与服务, 2006, (6): 321-324.
    [17] 张黎, 邱彦, 芮耀诚, 李铁军, 刘厚佳.  缺氧对血管内皮生长因子诱导主动脉内皮细胞通透性增加的调控研究 . 药学实践与服务, 2004, (3): 135-137.
    [18] 张旭静, 孔建龙, 黄久仪, 王桂清.  中药抗动脉粥样硬化作用研究进展 . 药学实践与服务, 2004, (6): 321-323.
    [19] 王晶, 潘勇华, 王旭明, 刘建飞.  光敏剂及其临床应用进展 . 药学实践与服务, 2002, (2): 67-70.
    [20] 戴生明, 朱铨英, 苏定冯.  血管紧张素Ⅱ(angiotensin Ⅱ)受体的研究进展 . 药学实践与服务, 1995, (3): 141-144,186.
  • 加载中
计量
  • 文章访问数:  3243
  • HTML全文浏览量:  378
  • PDF下载量:  1044
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-01-28
  • 修回日期:  2016-04-22

孤儿核受体NR4A1与动脉粥样硬化的研究进展

doi: 10.3969/j.issn.1006-0111.2016.04.002
    基金项目:  国家自然科学基金(81503155);上海市科委基金(14ZR1432200);上海交通大学医工交叉项目(YG2014MS21)

摘要: 孤儿核受体NR4A1是尚未发现特异性配体的转录因子之一,属于NR4A亚家族。早期研究发现,NR4A1可通过改变基因表达、翻译后修饰以及辅调蛋白间相互作用,调控细胞的增殖、凋亡、分化和应激反应。近年来研究发现其在动脉粥样硬化损伤部位表达异常,被认为是血管细胞功能紊乱过程中的关键调节基因。通过调控NR4A1基因的表达,可对平滑肌细胞的增殖和内皮细胞的激活产生重要影响,同时能够减少炎症反应、减少泡沫细胞的形成以及脂质沉积,抑制血管重塑,预防和阻止动脉粥样硬化的发生与发展。这些研究显示NR4A1可能成为研发预防和治疗动脉粥样硬化药物的新靶点。

English Abstract

干润, 霍炎, 黄金路, 杨全军, 郭澄. 孤儿核受体NR4A1与动脉粥样硬化的研究进展[J]. 药学实践与服务, 2016, 34(4): 292-296. doi: 10.3969/j.issn.1006-0111.2016.04.002
引用本文: 干润, 霍炎, 黄金路, 杨全军, 郭澄. 孤儿核受体NR4A1与动脉粥样硬化的研究进展[J]. 药学实践与服务, 2016, 34(4): 292-296. doi: 10.3969/j.issn.1006-0111.2016.04.002
GAN Run, HUO Yan, HUANG Jinlu, YANG Quanjun, GUO Cheng. Research progress on orphan nuclear receptor NR4A1 in atherosclerosis[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 292-296. doi: 10.3969/j.issn.1006-0111.2016.04.002
Citation: GAN Run, HUO Yan, HUANG Jinlu, YANG Quanjun, GUO Cheng. Research progress on orphan nuclear receptor NR4A1 in atherosclerosis[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 292-296. doi: 10.3969/j.issn.1006-0111.2016.04.002
参考文献 (30)

目录

    /

    返回文章
    返回